vs

Side-by-side financial comparison of CorMedix Inc. (CRMD) and Eventbrite, Inc. (EB). Click either name above to swap in a different company.

CorMedix Inc. is the larger business by last-quarter revenue ($128.6M vs $73.5M, roughly 1.7× Eventbrite, Inc.). CorMedix Inc. produced more free cash flow last quarter ($92.7M vs $-60.9M).

CorMedix Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel therapeutic products for the prevention and treatment of infectious, inflammatory and cardiorenal diseases. Its lead candidate targets catheter-related bloodstream infections, serving critical care and chronic dialysis patient populations primarily across North America and European markets.

Eventbrite is an American live events marketplace and website. The service allows users to browse, create, and promote local events. It is free to publish unlimited events of any size on Eventbrite.

CRMD vs EB — Head-to-Head

Bigger by revenue
CRMD
CRMD
1.7× larger
CRMD
$128.6M
$73.5M
EB
More free cash flow
CRMD
CRMD
$153.6M more FCF
CRMD
$92.7M
$-60.9M
EB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CRMD
CRMD
EB
EB
Revenue
$128.6M
$73.5M
Net Profit
$-8.2M
Gross Margin
83.4%
68.1%
Operating Margin
46.0%
-12.4%
Net Margin
-11.1%
Revenue YoY
-3.9%
Net Profit YoY
2.5%
EPS (diluted)
$0.20
$-0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRMD
CRMD
EB
EB
Q4 25
$128.6M
$73.5M
Q3 25
$104.3M
$71.7M
Q2 25
$39.7M
$72.8M
Q1 25
$39.1M
$73.8M
Q4 24
$76.5M
Q3 24
$77.8M
Q2 24
$84.6M
Q1 24
$86.3M
Net Profit
CRMD
CRMD
EB
EB
Q4 25
$-8.2M
Q3 25
$108.6M
$6.4M
Q2 25
$19.8M
$-2.1M
Q1 25
$20.6M
$-6.6M
Q4 24
$-8.4M
Q3 24
$-3.8M
Q2 24
$1.1M
Q1 24
$-4.5M
Gross Margin
CRMD
CRMD
EB
EB
Q4 25
83.4%
68.1%
Q3 25
89.3%
67.9%
Q2 25
95.3%
67.5%
Q1 25
95.9%
66.9%
Q4 24
68.2%
Q3 24
68.5%
Q2 24
70.9%
Q1 24
71.0%
Operating Margin
CRMD
CRMD
EB
EB
Q4 25
46.0%
-12.4%
Q3 25
49.2%
-1.3%
Q2 25
49.2%
-8.7%
Q1 25
51.5%
-13.2%
Q4 24
-10.2%
Q3 24
-11.5%
Q2 24
-7.6%
Q1 24
-8.8%
Net Margin
CRMD
CRMD
EB
EB
Q4 25
-11.1%
Q3 25
104.1%
8.9%
Q2 25
49.9%
-2.9%
Q1 25
52.8%
-9.0%
Q4 24
-11.0%
Q3 24
-4.8%
Q2 24
1.3%
Q1 24
-5.2%
EPS (diluted)
CRMD
CRMD
EB
EB
Q4 25
$0.20
$-0.08
Q3 25
$1.26
$0.06
Q2 25
$0.28
$-0.02
Q1 25
$0.30
$-0.07
Q4 24
$-0.09
Q3 24
$-0.04
Q2 24
$0.01
Q1 24
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRMD
CRMD
EB
EB
Cash + ST InvestmentsLiquidity on hand
$148.5M
$299.9M
Total DebtLower is stronger
$144.4M
Stockholders' EquityBook value
$405.3M
$179.1M
Total Assets
$826.1M
$647.2M
Debt / EquityLower = less leverage
0.81×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRMD
CRMD
EB
EB
Q4 25
$148.5M
$299.9M
Q3 25
$55.7M
Q2 25
$190.7M
Q1 25
$77.5M
Q4 24
$441.5M
Q3 24
$24.7M
Q2 24
$56.7M
Q1 24
$113.7M
Total Debt
CRMD
CRMD
EB
EB
Q4 25
$144.4M
Q3 25
$174.9M
Q2 25
$241.3M
Q1 25
$241.0M
Q4 24
$240.7M
Q3 24
$240.4M
Q2 24
$358.7M
Q1 24
$358.2M
Stockholders' Equity
CRMD
CRMD
EB
EB
Q4 25
$405.3M
$179.1M
Q3 25
$374.1M
$189.1M
Q2 25
$220.6M
$177.2M
Q1 25
$114.9M
$173.3M
Q4 24
$170.2M
Q3 24
$179.8M
Q2 24
$176.2M
Q1 24
$184.1M
Total Assets
CRMD
CRMD
EB
EB
Q4 25
$826.1M
$647.2M
Q3 25
$750.9M
$744.6M
Q2 25
$252.6M
$784.1M
Q1 25
$149.6M
$812.3M
Q4 24
$752.3M
Q3 24
$817.4M
Q2 24
$894.5M
Q1 24
$952.2M
Debt / Equity
CRMD
CRMD
EB
EB
Q4 25
0.81×
Q3 25
0.92×
Q2 25
1.36×
Q1 25
1.39×
Q4 24
1.41×
Q3 24
1.34×
Q2 24
2.04×
Q1 24
1.95×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRMD
CRMD
EB
EB
Operating Cash FlowLast quarter
$94.5M
$-60.8M
Free Cash FlowOCF − Capex
$92.7M
$-60.9M
FCF MarginFCF / Revenue
72.1%
-82.8%
Capex IntensityCapex / Revenue
1.3%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$172.8M
$17.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRMD
CRMD
EB
EB
Q4 25
$94.5M
$-60.8M
Q3 25
$30.9M
$36.7M
Q2 25
$30.0M
$-17.5M
Q1 25
$19.7M
$59.4M
Q4 24
$-45.3M
Q3 24
$44.6M
Q2 24
$-32.3M
Q1 24
$68.6M
Free Cash Flow
CRMD
CRMD
EB
EB
Q4 25
$92.7M
$-60.9M
Q3 25
$30.4M
$36.6M
Q2 25
$30.0M
$-17.5M
Q1 25
$19.7M
$59.4M
Q4 24
$-45.3M
Q3 24
$44.4M
Q2 24
$-32.4M
Q1 24
$68.2M
FCF Margin
CRMD
CRMD
EB
EB
Q4 25
72.1%
-82.8%
Q3 25
29.1%
51.1%
Q2 25
75.4%
-24.1%
Q1 25
50.5%
80.4%
Q4 24
-59.2%
Q3 24
57.1%
Q2 24
-38.3%
Q1 24
79.1%
Capex Intensity
CRMD
CRMD
EB
EB
Q4 25
1.3%
0.0%
Q3 25
0.5%
0.0%
Q2 25
0.1%
0.0%
Q1 25
0.0%
0.1%
Q4 24
0.0%
Q3 24
0.2%
Q2 24
0.1%
Q1 24
0.4%
Cash Conversion
CRMD
CRMD
EB
EB
Q4 25
Q3 25
0.28×
5.76×
Q2 25
1.51×
Q1 25
0.96×
Q4 24
Q3 24
Q2 24
-30.37×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CRMD
CRMD

Acquisition Of Melinta$52.9M41%
Melinta Portfolio$45.5M35%
Other$18.6M14%
Contract Revenue$7.4M6%
BARDA Agreement$4.2M3%

EB
EB

US$52.0M71%
Other$21.6M29%

Related Comparisons